1. Home
  2. VVPR vs ALXO Comparison

VVPR vs ALXO Comparison

Compare VVPR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoPower International PLC

VVPR

VivoPower International PLC

N/A

Current Price

$1.96

Market Cap

24.2M

Sector

Utilities

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$2.15

Market Cap

68.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VVPR
ALXO
Founded
2014
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
68.3M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
VVPR
ALXO
Price
$1.96
$2.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.00
AVG Volume (30 Days)
1.2M
815.4K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$0.41
52 Week High
$8.88
$2.66

Technical Indicators

Market Signals
Indicator
VVPR
ALXO
Relative Strength Index (RSI) 44.21 51.16
Support Level $1.20 $2.01
Resistance Level $2.90 $2.27
Average True Range (ATR) 0.29 0.20
MACD -0.04 -0.06
Stochastic Oscillator 11.60 19.53

Price Performance

Historical Comparison
VVPR
ALXO

About VVPR VivoPower International PLC

Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: